Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.
Taking Big Steps
MorphoSys' mission
25/01/2021
MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S....
12/01/2021
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug...
11/01/2021
MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
05/01/2021
MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing...
07/12/2020
Data Evaluating Tafasitamab with and without Lenalidomide in Combination...
02/12/2020
MorphoSys' Licensee Announces Approval by the European Commission for...
